A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes

Published:2013-06-17 Issue:11 Volume:48 Page:1437-1443
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Locke F,Agarwal R,Kunnavakkam R,van Besien K,Larson R A,Odenike O,Godley L A,Liu H,Le Beau M M,Gurbuxani S,Thirman M J,Sipkins D,White C,Artz A,Stock W

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201379.pdf

Reference41 articles.

1. Craddock C, Tauro S, Moss P, Grimwade D . Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005; 129: 18–34.

2. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397–404.

3. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 2005; 35: 965–970.

4. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730–3738.

5. Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D . Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009; 15: 30–38.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed;Cancer Medicine;2021-12-24

2. Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study;Cancer Medicine;2021-05

3. Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma;Leukemia & Lymphoma;2021-02-13

4. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response;Blood Advances;2020-10-22

5. Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies;Annals of Hematology;2018-08-24